Company intelligence / Profile preview

Cell2B Advanced Therapeutics

Cantanhede, Portugal

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Cell2B is a clinical-stage biotechnology company dedicated to developing advanced cellular therapies for the treatment of immune-related disorders. The company's core technology focuses on mesenchymal stem cell (MSC) based therapies designed to modulate the immune system and promote tissue repair. Its lead candidate, Cell-Ligand, is an off-the-shelf cell therapy aimed at treating acute Graft-versus-Host Disease (GvHD) and preventing rejection in organ transplantation. Founded as a spin-off from the MIT Portugal Program, Cell2B leverages proprietary cell processing techniques to provide scalable solutions for life-threatening immunological conditions.

Therapeutic areas: Immunology
Modalities: Cell therapyStem cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Cell2B Advanced Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cell2B Advanced Therapeutics.

Explore the full profile